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n healthy cells, Bax resides inactive in the cytosol because
its COOH-terminal transmembrane region (TMB) is
tucked into a hydrophobic pocket. During apoptosis, Bax
undergoes a conformational change involving NH
 
2
 
-terminal
exposure and translocates to mitochondria to release apop-
togenic factors. How this process is regulated remains
unknown. We show that the TMB of Bax is both necessary
and sufﬁcient for mitochondrial targeting. However, its
availability for targeting depends on Pro168 located within
I
 
the preceding loop region. Pro168 mutants of Bax lack
apoptotic activity, cannot rescue the apoptosis-resistant
phenotype of Bax/Bak double knockout cells, and are
retained in the cytosol even in response to apoptotic
stimuli. Moreover, the mutants have their NH
 
2
 
 termini
exposed. We propose that Pro168 links the NH
 
2
 
 and the
COOH terminus of Bax and is required for COOH-terminal
release and mitochondrial targeting once this link is broken.
 
Introduction
 
The Bcl-2 family members Bax and Bak are crucial mediators
of apoptosis during development and disease. Mice deficient
in both proteins exert gross developmental defects and are not
viable (Lindsten et al., 2000; Ranger et al., 2001). Moreover,
cells derived from these animals are resistant to numerous
apoptotic stimuli, including overexpression of proapoptotic
BH3-only proteins (Cheng et al., 2001; Wei et al., 2001;
Letai et al., 2002). BH3-only proteins, which act as sensors
of cellular stress, are activated by transcriptional up-regulation
and/or posttranslational modification following an apoptotic
stimulus (Puthalakath and Strasser, 2002). Once activated,
these proteins translocate to mitochondria inducing the acti-
vation of Bax/Bak by yet unknown mechanisms (Eskes et al.,
2000; Bouillet et al., 2001; Cheng et al., 2001; Letai et al.,
2002; Moreau et al., 2003). As a consequence, Bax and Bak
form oligomeric pores (Griffiths et al., 1999; Antonsson et
al., 2000, 2001) leading to the release of apoptogenic factors
from mitochondria into the cytosol (Jürgensmeier et al.,
1998; Rossé et al., 1998; Degenhardt et al., 2002).
Both Bax and Bak are tail anchored in the mitochondrial
outer membrane (MOM) via a COOH-terminal hydrophobic
transmembrane domain that is followed by basic residues
(Wolter et al., 1997; Goping et al., 1998; Nechushtan et al.,
1999; Suzuki et al., 2000; del Mar Martinez-Senac et al.,
2001). Bak constitutively localizes to the MOM where,
following an apoptotic stimulus, it is activated by conforma-
tional change and/or relieved from inhibitory proteins
(Griffiths et al., 1999). In contrast, Bax resides primarily in
the cytosol and requires an initial activation step to promote
its translocation to the MOM (Wolter et al., 1997; Goping
et al., 1998; Gross et al., 1998; Hsu and Youle, 1998; Capano
and Crompton, 2002). The solution structure of Bax revealed
that its transmembrane region (TMB) is folded back into a
hydrophobic pocket formed by its BH1, BH2, and BH3
domains (Suzuki et al., 2000). This conformation not only
prevents Bax targeting to the MOM but also inhibits the
binding of regulatory proteins to the hydrophobic pocket.
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Although the COOH-terminal TMB of Bax possesses
the properties of a transmembrane domain, it is still
unknown whether once released from the hydrophobic
pocket it also serves as a targeting signal for the MOM.
Nechushtan et al. (1999) have shown that although the last
21 amino acids of the TMB fused to GFP were insufficient
for mitochondrial targeting, they form a mitochondria tar-
geting signal when Ser184 was deleted or mutated to Val
or Ala. Ser184 stabilizes the inactive conformation of Bax
by forming a hydrogen bond with Asp98 in the hydropho-
bic pocket (Suzuki et al., 2000). Therefore, two events may
be necessary to target Bax to the MOM via the COOH-
terminal TMB: (1) breaking the TMB–pocket interaction,
and (2) increasing the hydrophobicity of Ser184 (mimick-
ing the S184A mutation). Alternatively, Cartron et al.
(2003) proposed that an NH
 
2
 
-terminal sequence of Bax
encompassing amino acids 20–37 mediates MOM target-
ing. Upon activation, Bax undergoes a conformational
change during which it exposes an NH
 
2
 
-terminal epitope,
but the significance of this exposure is unknown (Hsu and
Youle, 1997, 1998; Nechushtan et al., 1999). As NH
 
2
 
-ter-
minal exposure occurs simultaneously with mitochondrial
translocation, it may either unveil an NH
 
2
 
-terminal target-
ing sequence or facilitate the release of the TMB from the
hydrophobic pocket. Three proteins have recently been
suggested to regulate targeting of Bax to the MOM by
binding to the NH
 
2
 
 terminus (Ku70; Sawada et al., 2003),
the COOH terminus (humanin; Guo et al., 2003), or both
(14-3-3
 
 
 
; Nomura et al., 2003). The absence of these pro-
teins increased Bax translocation and cytotoxicity but only
in the presence of an apoptotic stimulus, indicating that
these proteins stabilize Bax in the cytosol but that addi-
tional proteins and/or posttranslational modifications are
required to trigger its conformational change and mito-
chondrial translocation.
In this work, we show that mitochondrial translocation of
Bax is mediated by the 23 amino acids of the COOH-termi-
nal TMB. Moreover, we define Pro168 in the loop preced-
ing the TMB as a crucial amino acid that couples NH
 
2
 
-ter-
minal exposure to the release of the COOH-terminal TMB.
Figure 1. Intracellular localization and 
cytotoxicity of transfected Bax and 
EGFP-Bax. (A) Confocal microscopy of 
HeLa cells transfected with Bax for 16 h 
using anti–N-Bax and an antibody against 
a mitochondrial protein (Mito Marker) 
for colocalization (Overlay). The fourth 
row shows an apoptotic cell (nuclear 
stain DRAQ5) with clustered Bax and 
cytochrome c released. (B) Direct fluo-
rescence of EGFP-Bax in HeLa cells 
together with the mito marker. 
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Results
 
Endogenous Bax is cytosolic and peripherally attached 
to mitochondria
 
Analysis of purified subcellular fractions of HEK293 re-
vealed that endogenous Bax mainly resides in the cytosol
and on the MOM (Fig. S1, A and B, available at http://
www.jcb.org/cgi/content/full/jcb.200309013/DC1). Most
of the mitochondrial form was extracted with alkali treat-
ment, indicating that Bax is peripherally attached to mito-
chondria (Fig. S1 C). Neither cytosolic nor mitochondrial
Bax was detected by immunofluorescence with NH
 
2
 
-termi-
nal–directed antibody, confirming that its NH
 
2
 
-terminal
epitope was obstructed (Fig. S1 D; Hsu and Youle, 1997,
1998). As previously shown (Griffiths et al., 1999), Bak be-
haved differently from Bax as it was not found in the cytosol
but instead stably inserted in the mitochondrial membrane
(alkali-resistant; Fig. S1, A and C).
 
Transfected Bax and EGFP-Bax effectively translocate 
to mitochondria and only residually remain soluble
 
Next, we determined the subcellular distribution and proap-
optotic activity of overexpressed Bax. Analysis by confocal
microscopy showed that 80–90% of HeLa cells transfected
with Bax (Fig. 1 A, bottom two rows) or EGFP-Bax (Fig. 1
B, bottom) displayed punctate Bax fluorescence staining,
diffuse cytosolic cytochrome 
 
c
 
, and fragmented nuclei. A
similar finding was obtained with Bax-transfected HEK293
cells (Fig. S2, Bax, available at http://www.jcb.org/cgi/
content/full/jcb.200309013/DC1). The punctate Bax fluo-
rescence was in proximity to, but not overlapping with, mi-
tochondrial markers (Fig. 1 A, Mito Marker). This finding is
consistent with recent works demonstrating that in apop-
totic cells Bax coalesces into clusters (Nechushtan et al.,
2001), which associate with mitochondrial fission sites (Kar-
bowski et al., 2002). The majority of overexpressed Bax was
found on the MOM (Fig. S1 B). Occasionally, both Bax
(Fig. 1 A, top two rows) and EGFP-Bax (not depicted) were
detected on elongated structures that perfectly colocalized
with a mitochondrial marker by confocal microscopy. These
cells did not yet exhibit morphological features of apoptosis,
suggesting that Bax was in an early stage of activation. Only
 
 
 
10% of the EGFP-Bax transfectants displayed a diffuse cy-
toplasmic staining (Fig. 1 B, top). The expression of cyto-
solic EGFP-Bax was consistently low, indicating that soluble
EGFP-Bax cannot accumulate to high levels (see Figs. S3
and S6A). These data show that upon overexpression, both
Bax and EGFP-Bax translocate efficiently to mitochondria
and do not require an exogenous apoptotic stimulus.
 
Tailless Bax and EGFP-Bax form cytoplasmic aggregates 
and are not targeted to mitochondria
 
To define the mitochondrial targeting sequence of Bax, we
first removed the entire COOH-terminal transmembrane
domain including the downstream basic-rich region (TMB)
in both Bax and EGFP-Bax (Fig. 2 A). The mutants were
transfected into HeLa cells and monitored for subcellular lo-
calization by fluorescence analysis (Fig. 2 B). In addition, we
determined their cytotoxicity by transfecting them into
HEK293 cells in the absence (for EGFP-Bax
 
 
 
TMB) or
presence (for Bax
 
 
 
TMB) of an EGFP expression plasmid
followed by FACS
 
®
 
 analysis of EGFP-positive, propidium
iodide (PI)–negative cells after 24 h (EGFP survival assay;
Fig. S3, available at http://www.jcb.org/cgi/content/full/
jcb.200309013/DC1). Both 
 
 
 
TMB mutants lacked proap-
optotic activity (Fig. S3), exhibited a cytoplasmic staining
(Fig. 2 B), and were primarily found in a cytosolic fraction
(Fig. 3 A). However, the mutants also formed aggregates,
which did not colocalize with mitochondria (Fig. 2 B), ER,
or lysosomes (not depicted). Strikingly, Bax
 
 
 
TMB was de-
tected with NH
 
2
 
-terminal antibodies, suggesting that the
NH
 
2
 
 terminus was open but not competent for mitochon-
drial targeting. To test whether or not the NH
 
2
 
-terminal
amino acids 20–37 could nevertheless contribute to mito-
chondrial targeting as previously reported (Cartron et al.,
2003), we exposed this domain by removing the first 20
amino acids (Bax
 
 
 
N20). This mutant was highly toxic upon
transfection into HEK293 cells (see Fig. 5 C), exhibited a
Figure 2. Bax lacking the TMB forms 
cytoplasmic aggregates. (A) Schematic 
structure and amino acid sequences of 
the COOH-terminal parts (TMB) of Bax 
and Bak. Pro168 of Bax and Pro187 of 
Bak are marked in bold and are situated 
at similar positions in a loop region in the 
X-domain ahead of the TMB. (B) Confocal 
microscopy of HeLa cells transfected with 
Bax TMB (using anti–N-Bax) or EGFP-
Bax TMB (codetection of EGFP and mito 
marker [red]). Note the cytoplasmic 
aggregates, which do not colocalize with 
mito marker. 
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punctate mitochondrial staining as wild-type Bax (Fig. 1 A
and not depicted), and was effectively targeted to mitochon-
dria in vitro (see Fig. 8 A). However, when we also removed
the TMB in the Bax
 
 
 
N20 mutant (Bax
 
 
 
N20
 
 
 
TMB), the
protein became cytoplasmic and nontoxic (unpublished
data). These data show that Bax requires the TMB, and not
the NH
 
2
 
-terminal amino acids 20–37, for mitochondrial
targeting. Moreover, through its interaction with the hydro-
phobic pocket, the TMB seems to protect Bax from inap-
propriate aggregation in the cytosol.
 
The COOH-terminal TMB region is both necessary and 
sufficient for mitochondrial targeting
 
It has been reported that the last 21 amino acids of the
COOH-terminal TMB domain are insufficient for mito-
chondrial targeting, unless its hydrophobicity is increased by
mutating Ser184 to Ala or Val (Nechushtan et al., 1999).
Thus, a regulatory mechanism mimicking this mutation may
be required to make the COOH terminus competent for mi-
tochondrial targeting. However, we envisaged the possibility
that sequences upstream of these 21 amino acids, which still
belonged to the TMB, could contribute to this targeting pro-
cess (Fig. 2 A). Therefore, we fused the last 21, 22, and 23
amino acids of Bax to EGFP and expressed the chimeras in
HeLa and HEK293 cells. In agreement with Nechushtan et
al. (1999), transiently transfected EGFP-21aa-C(Bax) resided
primarily in the cytoplasm (Fig. 3, A and B). Some of the fu-
sion protein was found in membrane fractions, presumably
because of the hydrophobicity of the 21 amino acids, but
these membranes were not specifically mitochondrial (Fig. 3
A). When the COOH terminus was extended to 22 amino
acids, the EGFP-22aa-C(Bax) fusion protein still displayed
cytosolic fluorescence staining (Fig. 3 B) and the majority
was found in the cytosol and on microsomes upon subcellu-
lar fractionation (Fig. 3 A). In contrast, the EGFP-23aa-
C(Bax) construct, which includes the entire TMB domain of
Figure 3. Mitochondrial targeting of Bax re-
quires the 23 amino acids of the TMB region. 
(A) Anti-GFP Western blots of subcellular frac-
tions from HEK293 cells expressing the indicated 
EGFP fusion constructs. To test the mitochondrial 
association of EGFP-23aa-C(Bax), isolated 
mitochondria were treated with sodium carbon-
ate (pH 12) to remove loosely attached proteins 
(Att), and the pellet was extracted with detergent 
(right, Ins). (B) EGFP (green) and anti–mito marker 
(red) fluorescence analysis of HeLa cells tran-
siently transfected with the indicated EGFP 
fusion constructs. 
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Bax (Fig. 2 A), specifically colocalized with mitochondrial
markers (Fig. 3 B). At least one basic residue was required at
the end of the TMB for correct targeting (see supplemental
material and Fig. S4, available at http://www.jcb.org/cgi/
content/full/jcb.200309013/DC1). As expected for a TMB
domain that serves as a targeting and membrane insertion de-
vice, the EGFP-23aa-C(Bax) localized with and inserted into
the MOM (Fig. 3 A). Extending the TMB targeting se-
quence to its upstream X-domain (EGFP-X-TMB(Bax); Fig.
2 A) did not alter mitochondrial targeting (Fig. 3, A and B),
indicating that the 23 amino acids of the TMB are necessary
and sufficient for mitochondrial targeting.
 
Pro168 regulates NH
 
2
 
-terminal exposure and the 
release of the COOH-terminal TMB targeting sequence
 
We assumed that the release of the COOH-terminal TMB
from its hydrophobic pocket requires a conformational
change that is regulated by amino acids in the loop region di-
rectly upstream of the 
 
 
 
-helical TMB (Fig. 2 A). This loop is
solvent-exposed and may be modified or bound by regulatory
proteins implicated in the release process (Fig. 4). All five
amino acids within this loop region (X-domain, Phe165–
Thr169) were mutated and their intracellular localization was
determined after transient transfection of HeLa or HEK293
cells using NH
 
2
 
-terminal antibodies. Most point mutations
in the loop region did not affect the mitochondrial targeting
of Bax, and transfectants had an identical appearance to those
overexpressing wild-type Bax (unpublished data). However,
when Pro168 was deleted (Bax
 
 
 
P168) or substituted for Ala
(Fig. 2 A, Bax(P168A)), 80–90% of both HeLa (Fig. 5 A) or
HEK293 transfectants (Fig. S2) displayed a diffuse cytoplas-
mic Bax staining, were stretched out, and had intact nuclei.
Moreover, the Pro168 mutants were only slightly cytotoxic
(Fig. 5 C). Strikingly, both Bax
 
 
 
P168 and Bax(P168A) were
detected with NH
 
2
 
-terminal antibodies, indicating that their
NH
 
2
 
-terminal epitopes were exposed in the cytoplasm. This
exposure was confirmed by using the NH
 
2
 
-terminal Bax anti-
body to immunoprecipitate stably expressed FLAG-tagged
Bax or Bax(P168A) from HeLa cell extracts (Fig. 5 B). Only
low levels of FLAG-Bax could be captured with the antibody,
whereas FLAG-Bax(P168A) was effectively immunopre-
cipitated from the lysate although both proteins were ex-
pressed at similar levels (Fig. 5 B). These data show that the
Bax
 
 
 
P168 and Bax(P168A) mutants had the NH
 
2
 
-terminal
epitope exposed but failed to translocate to mitochondria and
induce apoptosis.
To further substantiate that the release of the COOH-ter-
minal TMB was dependent on Pro168 and not on the expo-
sure of the NH
 
2
 
-terminal epitope, we deleted the NH
 
2
 
-ter-
minal 20 amino acids in the Bax(P168A) mutant. This
double mutant confirmed our results, suggesting that Bax is
targeted to the MOM via its COOH-terminal TMB rather
than the NH
 
2
 
-terminal amino acids 20–37. Bax
 
 
 
N20/
P168A exhibited a diffuse cytoplasmic staining after trans-
fection into HeLa cells (Fig. 5 A) and was as slightly cyto-
toxic in the HEK293/EGFP survival assay as Bax(P168A)
(Fig. 5 C). Thus, Bax requires Pro168 for COOH-terminal
unleashment, mitochondrial targeting, and cytotoxicity even
when the NH
 
2
 
 terminus is deleted.
Proline does not have the ability to form a classical hydro-
gen bond within the protein backbone. This property im-
poses some restrictions on the secondary and tertiary struc-
tures of proteins defining its role as a helix breaker. If Pro168
were to play a purely structural role in the TMB of Bax, its
replacement by another helix-breaking amino acid such as
glycine would not be expected to change the mitochon-
drial targeting and cytotoxic properties of Bax. However, a
Bax(P168G) mutant was indistinguishable from Bax
 
 
 
168 or
Bax(P168A) with respect to survival activity, cytoplasmic re-
tention, and NH
 
2
 
-terminal exposure (Fig. 5, A and C). This
was also the case when Pro168 was mutated to Glu, a helix-
forming amino acid (Fig. 5, A and C, Bax(P168E)). These
results suggest that the helix-breaking capacity of Pro168 is
not involved in Bax COOH-terminal TMB release. To con-
firm that Pro168 was responsible for the release and not the
targeting function of the TMB, we created an EGFP-X-
TMB(Bax) (loop-TMB) fusion protein in which Pro168 was
substituted for Ala. This EGFP-X(P168A)-TMB(Bax) pro-
tein was targeted to mitochondria as efficiently as the EGFP-
X-TMB(Bax) construct (Fig. 3 B). Together, our data sug-
gest that Pro168 is not part of the COOH-terminal TMB
targeting sequence but is a crucial amino acid for regulating
the release of this targeting sequence from the hydrophobic
pocket. Most importantly, Pro168 inhibits NH
 
2
 
-terminal ex-
Figure 4. Modeling of the solution 
structure of Bax in the region of X-TMB 
(Pro168). Molecular modeling of Bax 
using the Deep View Swiss-PDB viewer 
(Schwede et al., 2003) and based on the 
Bax NMR solution coordinate data from 
Suzuki et al. (2000). Phe165–Trp170 are 
in a solvent-exposed loop of which 
Pro168 is at the turning point. Pro168 is 
in the trans configuration and is close to 
Trp170, the first amino acid in the TMB 
targeting sequence. 
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posure indicating that it somehow couples the NH
 
2
 
 terminus
to the loop-TMB region of Bax.
 
Pro168 mutants of Bax are not aberrantly folded 
and reside in the cytoplasm in a stable form
 
It is possible that mutations in Pro168 changed the structure
of Bax in a way that the protein would aggregate and be rap-
idly degraded. To exclude this possibility, we determined the
size of Bax protein complexes in the cytosol of FLAG-Bax–
and FLAG-Bax(P168A)–transfected HeLa cells by gel filtra-
tion analysis. As shown in Fig. S5 A (available at http://
www.jcb.org/cgi/content/full/jcb.200309013/DC1), endoge-
nous Bax, overexpressed FLAG-Bax, and mutant FLAG-
Bax(P168A) were all immunodetected in fractions corre-
sponding to monomeric Bax (20–35 kD). No high molecular
mass aggregates were observed for any of the Bax forms. Most
importantly, both FLAG-Bax and FLAG-Bax(P168A) oligo-
merized in the presence of the nonionic detergent NP-40 in-
dicating that they undergo the same conformational change
as Bax (Fig. S5 B). In addition, the Pro168 mutants of Bax
were stable proteins. The steady-state expression of EGFP-
Bax(P168A) and EGFP-Bax(P168G) proteins did not signifi-
cantly change for 24–48 h after transfection (Fig. S6 A, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200309013/
DC1), nor were the proteins rapidly degraded in the presence
of CHX (Fig. S6 B). In contrast, EGFP-Bax protein levels de-
creased (Fig. S6 B) and were almost lost at 24–48 h after
transfection (Fig. S6 A), presumably due to the loss of EGFP-
Bax–expressing cells by apoptosis (Figs. S3 and S6 B).
 
Pro168 mutants of Bax do not translocate to 
mitochondria after staurosporine treatment
 
Apoptotic stimuli such as the kinase inhibitor staurosporine
provoke the exposure of the NH
 
2
 
-terminal helix 
 
 
 
1 and mi-
tochondrial translocation of endogenous cytosolic Bax (Es-
kes et al., 1998). Similarly, staurosporine can trigger the mi-
tochondrial translocation of transfected cytosolic GFP-Bax,
and hence promotes apoptosis in cells that express low levels
of GFP-Bax (Nechushtan et al., 1999). To investigate the
contribution of Pro168 to the staurosporine-induced trans-
Figure 5. Pro168 and Trp170 mutants of Bax 
reside in the cytoplasm in an inactive form and 
have their NH2 termini exposed. (A) Anti–N-Bax 
and mito marker coimmunofluorescence analysis 
of HeLa cells transfected with Pro168 and Trp170 
mutants of Bax. The yellow mitochondrial staining 
is due to the strong mitochondrial red staining 
shining through cytoplasmic green fluorescence. 
An NH2-terminally truncated Bax N20/P168A 
mutant is still cytoplasmic as detected by anti-Bax 
(aa43–61) immunostaining. (B) Anti–N-Bax immuno-
precipitation (IP) from cytosols of HeLa cells stably 
expressing FLAG-Bax or FLAG-Bax(P168A) followed 
by anti-FLAG Western blotting. Only FLAG-
Bax(P168A) but not FLAG-Bax was immunoprecip-
itated, although both proteins were expressed at 
similar levels (Cytosol). (C) Survival assay. Percentage 
of EGFP-positive/PI-negative cells, determined by 
FACS
®, after cotransfection of HEK293 cells with 
EGFP and either pcDNA3 or the indicated Bax or 
Bak construct. The values were normalized to 
pcDNA3/EGFP (co)transfections where maximal 
survival (100%) is seen. Values are the mean of 
five independent experiments   SEM. 
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location of GFP-Bax, we generated Pro168 mutants of
EGFP-Bax and studied their intracellular localization in
mouse embryo fibroblasts (MEFs) in either the presence or
absence of 1 
 
 
 
M staurosporine by direct fluorescence (Fig. 6
A). In addition, we tested the apoptotic potential of the
EGFP variants in HEK293 cells using FACS
 
®
 
 analysis (Fig.
6 B). EGFP alone did not induce apoptosis and was highly
expressed in the cytoplasm of both untreated and staurospo-
rine-treated MEFs (Fig. 6). In contrast, most of the EGFP-
Bax transfectants were lost (Fig. 6 B). The few surviving cells
contained low levels of cytosolic EGFP-Bax of which all
translocated to mitochondria in response to staurosporine
(Fig. 6 A). As shown for Bax(P168A) (Fig. 5 C), EGFP-Bax
variants in which Pro168 was mutated to Ala or Gly were
only mildly toxic (Fig. 6 B) and localized to the cyto-
plasm (Fig. 6 A, left) and a cytosolic fraction (Fig. 3 A).
Strikingly, even after 4 h of staurosporine treatment, the ma-
jority of MEFs expressing EGFP-Bax(P168A) and EGFP-
Bax(P168G) were still stretched out, contained intact nuclei,
and retained the mutant proteins in the cytoplasm (Fig. 6 A,
right). Thus, Pro168 is required for the release of the
COOH-terminal TMB targeting sequence and the subse-
quent mitochondrial translocation and cytotoxicity of Bax
even in the presence of an external apoptotic stimulus.
 
Pro168 mutants of Bax do not sensitize Bax/Bak DKO 
cells to drug-induced apoptosis
 
MEFs deficient in both Bax and Bak (DKO) are highly resis-
tant to drug-induced apoptosis (Wei et al., 2001). If Pro168
mutants of Bax lack proapoptotic activity, they should not be
able to sensitize these cells for apoptosis. We stably expressed
EGFP-Bax and EGFP-Bax(P168A) to approximately the
same levels in Bax/Bak DKO MEFs (Fig. 7 A) and deter-
mined the extent of etoposide-induced apoptosis by FACS
 
®
 
analysis of PI-positive cells. As shown in Fig. 7 B, EGFP-Bax
resensitized the DKO MEFs for apoptosis to almost the level
of wild-type MEFs. In contrast, the EGFP-Bax(P168A)–
expressing cells remained resistant to the drug. These data
confirm the lack of proapoptotic activity of Bax(P168A).
 
Disruption of the TMB–pocket interaction facilitates 
in vitro mitochondrial targeting
 
To further study the mechanisms of TMB unleashment, we
developed an in vitro assay in which the cDNAs of Bax and
its mutants were transcribed/translated in rabbit reticulocyte
lysates in the presence of [
 
35
 
S]methionine. The translation
mixture was centrifuged to eliminate protein clusters formed
during translation, and then added to isolated mitochondria
(Fig. 8). Only 
 
 
 
20% of Bax synthesized in vitro was tar-
geted to mitochondria. In contrast, Bcl-x
 
L
 
, another member
of the Bcl-2 family was effectively targeted to mitochondria
in vitro (
 
 
 
60%; Fig. 8) presumably due to the constitutive
exposure of its TMB (Kaufmann et al., 2003). We predicted
that if inefficient mitochondrial targeting of Bax were due to
the folding of the TMB into the hydrophobic pocket, any
disruption of this interaction would enhance mitochondrial
association. As expected, a Bax mutant in which the entire
pocket was destroyed by deleting helices 
 
 
 
5 and 
 
 
 
6 (Bax
 
 
 
5/
6) was as efficiently targeted to mitochondria as Bcl-x
 
L
 
 (Fig.
8). Increased mitochondrial targeting was also observed with
Bax(S184A), in which hydrogen bonding between the TMB
and the pocket was disrupted, as well as with Bax
 
 
 
N20,
which lacked the first 20 amino acids of Bax (Fig. 8 A).
However, the targeting efficiency of these mutants was
somewhat lower than for Bcl-x
 
L
 
 or Bax
 
 
 
5/6. These results
suggest that the NH
 
2
 
 terminus interacts with the COOH-
terminal TMB and that both the removal of the NH
 
2
 
 termi-
nus and a breakage of the TMB–pocket interaction facili-
tates mitochondrial targeting.
We used the in vitro transcription/translation (IVTT) as-
say to confirm the role of Pro168 in the unleashment and
Figure 6. Pro168 mutants of Bax do not translocate to mitochondria 
in response to staurosporine. (A) EGFP (green) and anti–mito marker 
(red) fluorescence analysis of MEFs transfected with EGFP, EGFP-Bax, 
or two EGFP-Bax Pro168 mutants either untreated or treated with 
1  M staurosporine (STS) for 4 h. Only 10% of the transfectants 
express cytosolic EGFP-Bax, whereas  80% exhibited cytosolic 
EGFP-Bax(P168A) or EGFP-Bax(P168G) fluorescence. In response to 
STS, the Pro mutants are retained in the cytosol and the cells remain 
stretched out. (B) Survival assay of the EGFP fusion proteins in HEK293 
cells was performed as described in Fig. 5 C. Values were normalized 
to EGFP and are the mean of five independent experiments   SEM. 
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mitochondrial targeting of the TMB of Bax. As variants of
Bax with Pro168 mutations were observed to be cytoplas-
mic, they were expected to be targeted to the mitochondria
to a lesser extent than Bax in vitro. Indeed, the amounts of
Bax
 
 
 
P168, Bax(P168A), Bax(P168G), and Bax(P168E) re-
covered in the mitochondrial pellet were approximately half
that of wild-type Bax under the same experimental condi-
tions (Fig. 8 A and not depicted).
 
Trp170 cooperates with Pro168 for TMB unleashment
 
Trp170 is the first amino acid of the TMB mitochondrial
targeting sequence (Fig. 3, A and B). In addition, as seen in
the structure of Bax (Fig. 4), this amino acid is in close con-
tact with Pro168. Therefore, we wondered whether or not
Trp170 would assist Pro168 in unleashing the TMB by
forming a binding pocket for a putative TMB releasing fac-
tor. For that purpose, we generated Bax mutants in which
Trp170 was mutated to Ala. As shown in Fig. 5 (A and C),
Bax(W170A) had its NH
 
2
 
 terminus exposed, was retained in
the cytoplasm, and was only mildly cytotoxic after transfec-
tion into HEK293 cells. A double mutant of Bax in which
both Trp170 and Pro168 were mutated to Ala (Bax(P168A/
W170A)) did not induce apoptosis at all (Fig. 5 C). These
data indicate that Trp170 is not only part of the TMB tar-
geting sequence but cooperates with Pro168 in regulating
NH
 
2
 
-terminal exposure and the release of the TMB for mi-
tochondrial targeting.
 
Proline-directed release of the COOH-terminal TMB 
does not occur with the related protein Bak
 
As shown in Fig. S1 C, endogenous Bak stably associates
with mitochondria in nonapoptotic cells. Bak possesses a Pro
residue, Pro187, at a similar position upstream of the TMB
as Bax (Fig. 2 A). To determine if mitochondrial targeting of
Bak was also dependent on a proline-mediated release of its
TMB region, we determined the targeting properties and cy-
totoxicity of Bak and two Pro187 mutants, Bak(P187G) and
Bak(P187E), using the in vitro mitochondrial targeting and
the EGFP survival assays. In contrast to Bax, wild-type Bak
and the Bak(P187G) and Bak(P187E) mutants were effec-
tively targeted to mitochondria after in vitro translation (Fig.
8 B) and were cytotoxic (Fig. 5 C, bottom). As it was re-
ported that Bak and Bax can form heterodimers or oligomers
(Mikhailov et al., 2003), and this formation may disrupt the
interaction between the TMB and the hydrophobic pocket of
Bax, we further tested if Bak could assist Bax in the TMB un-
Figure 7. Proapoptotic activity of EGFP-Bax and EGFP-Bax(P168A) 
in Bax/Bak DKO MEFs. (A) Bax/Bak-deficient MEFs (DKO) were 
transduced with retroviruses carrying EGFP-Bax/pLPCx or EGFP-
Bax(P168A)/pLPCx plasmids. Mixed populations of cells were FACS
®-
sorted, grown-up, and analyzed for the expression of the respective 
proteins by anti-GFP Western blotting. As controls, parental MEFs 
(WT) and DKO MEFs were used. (B) The cells described in A were 
left untreated or treated with 100  M etoposide (etopo) for 24 h and 
stained with 10  g/ml propidium iodide (PI), and the percentage of 
PI-positive dead cells was determined by FACS
® analysis. The values 
are taken from fluorescence intensity  10
2 of the FACS
® histogram 
and are the mean of four independent experiments   SEM.
Figure 8. Targeting of in vitro translated Bax, Bak, and mutants to 
isolated mitochondria. Autoradiography of [
35S]methionine-labeled 
IVTT Bax, Bak, and mutants bound to mitochondria (Mito) or 
remaining in the supernatant after spinning down the organelles 
(Sup). Bcl-xL is used as a control because it translocates efficiently to 
mitochondria in vitro (Kaufmann et al., 2003). In one lane, Bax and 
Bak were mixed 1:1 before adding to mitochondria (B). This mixture 
did not enhance Bax translocation. Asterisks denote a Bax protein 
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leashment and mitochondrial targeting. However, the extent
of Bax translocation to mitochondria remained low when
Bax and Bak were cotranslated in vitro (Fig. 8 B). Thus, pro-
line-directed unleashment of the TMB mitochondrial target-
ing sequence is a regulatory mechanism specific for Bax and
does not seem to play a role in the mitochondrial targeting of
other Bcl-2 family members such as Bak.
Discussion
Our work provides novel insights into the mechanisms by
which Bax translocates to the MOM where it carries out its
function. First, we show that in nonapoptotic cells, Bax is
not only cytosolic but also peripherally attached to mito-
chondria. Second, we define the last 23 amino acids of the
COOH-terminal TMB domain as both necessary and suffi-
cient for mitochondrial targeting and membrane insertion of
Bax. Third, we identify Pro168 as a residue essential for reg-
ulating the conformational change of Bax leading to the ex-
posure of the NH2 terminus and the release of the TMB
from its hydrophobic pocket.
Although Bax is reported to reside exclusively in the cyto-
plasm of tissue cells (Hsu and Youle, 1998; Letai et al.,
2002), we confirm that there is an appreciable amount of the
protein peripherally attached to mitochondria in cultured cell
lines (Goping et al., 1998; Desagher et al., 1999). We suggest
that this interaction of Bax with the MOM is not dependent
on the TMB targeting sequence for the following reasons: (a)
EGFP-TMB is inserted in the MOM rather than loosely at-
tached (alkaline-sensitive; Fig. 3 A); (b) small amounts of en-
dogenous Bax can also reside on other organelle membranes,
such as the ER, but in an alkaline-sensitive form (Scorrano et
al., 2003; Zong et al., 2003); and (c) the NH2 terminus of al-
kaline-sensitive mitochondrial Bax is not exposed (Fig. S1
D). These findings suggest that endogenous Bax remains in
an inactive conformation on the membranes of unstimulated
cells before undergoing the structural changes required for
membrane insertion and proapoptotic activity.
It has remained controversial whether or not the transloca-
tion of Bax to mitochondria in apoptotic cells is mediated via
its NH2 or COOH terminus. Recently, an NH2-terminal se-
quence at amino acids 20–37 ( -helix 1) has been reported
to act as a mitochondrial targeting signal when fused to GFP
(Cartron et al., 2003). However, we think that this sequence
does not mediate the rapid, early Bax translocation in apop-
totic cells. First, it is preceded by an NH2-terminal inhibitory
domain called apoptosis-regulating targeting domain (ART;
amino acids 1–20), which must first be cleaved off to expose
the targeting signal (Goping et al., 1998; Gao and Dou,
2000). Indeed, a calpain-like protease has been shown to me-
diate ART cleavage (Wood et al., 1998; Gao and Dou, 2000;
Choi et al., 2001; Toyota et al., 2003). Because proteolysis is
a late event in apoptosis and is prevented by calpain inhibi-
tors without affecting Bax translocation and cell death, it
probably serves to accelerate, rather than initiate, Bax translo-
cation and apoptotic signaling through mitochondria (Cao et
al., 2003). Second, Bax mutants lacking the ART sequence
(Bax N20) still depended on the COOH-terminal TMB
(not depicted) and Pro168 (Fig. 5 A, Bax N20/P168A) for
mitochondrial targeting. Third, Cartron et al. (2003) found
that the NH2-terminal targeting sequence only mediates an
alkaline-sensitive interaction of Bax with the mitochondrial
membrane, indicating that the NH2 terminus may contrib-
ute to the relatively nonspecific interaction of endogenous
Bax in nonapoptotic cells. However, based on our results, the
23 amino acids of the COOH-terminal TMB mediate Bax
translocation and MOM insertion in apoptotic cells.
In many apoptotic systems, Bax activation has been de-
fined by the exposure of an NH2-terminal epitope (Hsu and
Youle, 1997, 1998; Nechushtan et al., 1999). Although this
exposure coincides with Bax translocation to mitochondria,
it has remained difficult to explain why it can occur hours
before cytochrome c release and be reversible upon removal
of the apoptotic stimulus (Gilmore et al., 2000; Valentijn et
al., 2003). These findings indicate that NH2-terminal expo-
sure is not the commitment step in Bax activation. Why
then is it important and what does it initiate? One possibility
is that the NH2 terminus interacts with the COOH termi-
nus either directly or via a binding protein as previously pro-
posed (Fig. 9; Ruffolo et al., 2000). Ku70 has recently
been identified as an NH2-terminal binding protein of Bax
(Sawada et al., 2003). Overexpression of Ku70 retains Bax in
the cytoplasm, supporting the notion that it may prevent the
release of the COOH-terminal TMB. Similarly, a COOH-
terminal binding protein, humanin, was shown to prevent
Bax translocation after transfection into human cells (Guo et
al., 2003). However, neither reducing endogenous Ku70 nor
humanin expression sensitized cells for apoptosis or Bax
translocation in the absence of an apoptotic stimulus. This
finding implies that the loss of NH2- or COOH-terminal
binding proteins is not sufficient for Bax activation and that
an additional, probably energy-requiring step, provided by
an apoptotic stimulus is needed to provoke the release of the
COOH-terminal TMB (Suzuki et al., 2000; Fig. 9). A puta-
tive trigger could be a member of the subfamily of BH3-only
proteins because these proteins are known to be activated in
response to apoptotic stimuli and to bind to the hydropho-
bic pocket of multidomain Bcl-2 family members with high
affinity (Puthalakath and Strasser, 2002). Such a mechanism
has been proposed for disengaging the COOH terminus
from the hydrophobic pocket of the survival factor Bcl-w
(Denisov et al., 2003; Hinds et al., 2003) and for relieving
the COOH-terminal TMB of Bax by the NH2-terminal do-
main (Ruffolo et al., 2000). However, Liu et al. (2003) re-
cently presented the structure of Bcl-xL complexed with a
fragment of the BH3-only protein Bim and predicted, based
on the structural homology between Bcl-xL and Bax, that it is
the  -helix 8 rather than the COOH-terminal TMB ( 9)
that is displaced by the binding of Bim to Bax. Consistent
with this view, Suzuki et al. (2000) suggested that the bind-
ing of a BH3-only protein to Bax does not confer enough
energy for the release of the COOH-terminal TMB.
We provide evidence that Pro168 is a crucial amino acid
for regulating both NH2-terminal exposure and the release of
the COOH-terminal TMB. First, Pro168 mutants of Bax
had their NH2 termini exposed in the cytoplasm in a non-
toxic form. This exposure shows that NH2-terminal exposure
is neither sufficient for targeting nor for Bax activation and
cytotoxicity. It is possible that the Pro mutants were detected
with NH2-terminal antibodies because endogenous cytoplas-1030 The Journal of Cell Biology | Volume 164, Number 7, 2004
mic Bax saturated an NH2-terminal binding protein. How-
ever, Nechushtan et al. (1999) reported that transfection of
an S184K mutant of Bax, which was constitutively retained
in the cytoplasm, did not have its NH2 terminus exposed.
Moreover, as shown here, Pro168 mutants even remained in
the cytoplasm in response to an apoptotic stimulus such as
staurosporine, which is known to provoke Bax translocation.
Thus, although COOH-terminal releasing factors (the en-
ergy-requiring step) induced by the apoptotic stimulus may
have been present, the COOH-terminal TMB was probably
not released due to a mutation of Pro168. Our data show
that it is not the helix-breaking activity of Pro168 that deter-
mines COOH-terminal release, but that a binding protein or
posttranslational modification on Pro168 could be the trig-
ger. In this respect, Trp170, which is the first amino acid of
the TMB targeting sequence, may contribute to a protein
binding site as it is juxtaposed to Pro168 in the cytosolic
structure (Fig. 4), and Bax variants mutated at Trp170 exhib-
ited NH2-terminal exposure and nonapoptotic cytoplasmic
localization like the Pro168 mutants (Fig. 5).
What kind of modification or binding activity could oper-
ate on Pro168 and Trp170? Prolines can be the target amino
acids for prolyl cis/trans isomerases (PPIases). These enzymes
accelerate the slow cis-to-trans isomerization of prolines
(Galat and Metcalfe, 1995). Pro368 of diphtheria toxin has
been suggested to be a target site for a PPIase and to contrib-
ute to the conformational change required for the pore forma-
tion of the toxin in the membrane (Johnson et al., 1993).
Diphtheria toxin is structurally related to Bax (Muchmore et
al., 1996; Suzuki et al., 2000), and, thus, isomerization of
Pro168 may be a crucial step for TMB unleashment, mi-
tochondrial targeting, and membrane insertion. Molecular
modeling of the soluble Bax structure revealed that the
Pro168 is in its trans configuration (Fig. 4). Thus, PPIases
could favor/accelerate the folding process of Bax after its syn-
thesis on ribosomes. However, our preliminary data suggest
that cyclosporine A and rapamycin, inhibitors against the clas-
sical PPIases cyclophilin and TOR, respectively, had no effect
on Bax translocation and cytotoxicity. This finding does not
exclude the participation of another PPIase, such as Pin1,
which has recently been shown to regulate the apoptotic activ-
ity of p53 (Zacchi et al., 2002; Zheng et al., 2002). Alterna-
tively, Pro168 may bind or release specific proteins after apop-
tosis stimulation or be the target for a posttranslational
modification such as hydroxylation (Kivirikko et al., 1989).
Together, we propose the following model for the mito-
chondrial translocation and activation of Bax in apoptotic
cells (Fig. 9). In the cytosol of nonapoptotic cells, the NH2
terminus is linked to Pro168 (and Trp170) either directly
(Fig. 9 B) or via a binding protein (Fig. 9 A) or a posttransla-
tional modification (Fig. 9 C) and prevents COOH-termi-
nal unleashment. In response to an apoptotic stimulus, the
interaction between the NH2 and COOH terminus is dis-
rupted by the degradation of the binding protein or other
modifications. Although this process leads to the exposure of
the NH2 terminus and sensitizes Bax for activation, it is not
sufficient for COOH-terminal release. An additional bind-
ing protein or a posttranslational modification is required
that acts on Pro168 (and Trp170) and provides the energy
to release the COOH-terminal TMB for mitochondrial tar-
geting. Further work is required to identify these regulators
of NH2-terminal exposure and COOH-terminal release.
They will be promising targets for new therapies against dis-
eases in which Bax translocation needs to be stimulated
(cancer) or inhibited (neurodegeneration).
Materials and methods
cDNAs and site-directed mutagenesis
All EGFP constructs were made in the pEGFP-C1, -C2, or -C3 vectors (In-
vitrogen). The cDNAs for FLAG-Bax, the various Bax and Bak mutants, and
the EGFP fusion proteins were generated by PCR or standard cut and paste
techniques as described in the online supplemental material. All constructs
were verified by dideoxynucleotide sequencing.
Immunofluorescence analysis
HeLa cells, HEK293 cells, and MEFs were grown on 17-mm glass cover-
slips until they reached 70% confluence. The cells were transfected with
0.8  g of plasmid DNA and 2.4  l of Superfect for 3 h at 37 C and placed
in growth medium. After 16 h, the cells were fixed in 4% PFA and perme-
Figure 9. Integrated model of mitochondrial 
association of Bax in healthy and apoptotic cells. 
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abilized with 0.05% saponin and ice-cold acetone. The cells were incu-
bated with anti–N-Bax (detecting amino acids 1–20; Upstate Biotechnol-
ogy; 1:200) in the presence of either anti–cytochrome c (BD Biosciences;
1:50), anti-mitochondria (BP128; The Binding Site Ltd.; 1:300), or anti–
hBcl-2 (clone 124; DakoCytomation; 1:100) as colocalization markers for
90 min followed by Alexa Fluor 488 (green)– and/or Alexa Fluor 546 (red)–
conjugated goat anti–rabbit or anti–mouse secondary antibodies (Molecu-
lar Probes) for another 60 min. After postfixation in 4% PFA containing 2
 g/ml Hoechst 33342 dye (Molecular Probes) or DRAQ5 (Biostatus Ltd.),
the antifading agent Slowfade (Molecular Probes) was added, and the cells
were viewed under a laser scanning microscope (model LSM 410; Carl
Zeiss MicroImaging, Inc.) using a 488-nm Argon Laser (for green fluores-
cence) and HeNe-Laser at 543 nm (for red fluorescence) and a HeNe-Laser
at 633 nm for DRAQ5. Pictures were processed with Carl Zeiss MicroIm-
aging, Inc. software.
Protein expression, subcellular fractionation, and sodium 
carbonate extraction
HEK293 cells were grown on 150-mm plates until  80% confluent, and
then transfected with 10  g of plasmid DNA using 25  l of Superfect
(QIAGEN) as described by the manufacturer. After 3–6 h, the Superfect–
DNA complexes were removed and the cells were cultured in fresh me-
dium for another 24–48 h. The cells were homogenized; and fractionation
into mitochondria, microsomes, and cytosol was performed by sucrose
gradient centrifugation exactly as described in Kaufmann et al. (2003).
Submitochondrial fractionation and sodium carbonate extraction of mito-
chondria were performed as described by Kaufmann et al. (2003). Nuclear
fractions are not shown because they could not be reproducibly deprived
of cosedimenting or aggregated mitochondria and unlysed cells. For pro-
tein stability experiments, 10  g/ml cycloheximide was added to the cells
at 24 h posttransfection for 1–4 h, and total extracts were prepared (Kauf-
mann et al., 2003).
Western blotting
30  g of protein were immunodetected by anti–N-Bax (1:2,000), anti–
N-Bak (1:2,000), anti–GFP/JL-8 (Living colors
®; Invitrogen; 1:1,000), anti-
KDEL (StressGen Biotechnologies; 1:1,000), anti-grp78/Bip (StressGen
Biotechnologies, 1:1,000), anti–COX-I (Molecular Probes; 1:300), or anti-
FLAG (Sigma-Aldrich, 1:1,000) primary antibodies followed by per-
oxidase-coupled, goat anti–rabbit or anti–mouse secondary antibodies
(Sigma-Aldrich). Immunodetection was performed by ECL (Pierce Chemi-
cal Co.). Equal protein loading was confirmed by staining the membrane
amido black or probing with an antibody against the ubiquitously ex-
pressed protein 14-3-3  (Santa Cruz, 1:2,000).
Generation of stable cell lines and immunoprecipitation
The FLAG-Bax and FLAG-Bax(P168A) and the EGFP-Bax and EGFP-
Bax(P168A) cDNAs were cloned into the low expression retroviral vectors
pLxIN and pLPCx, respectively (CLONTECH Laboratories, Inc.). Infectious
retroviral virons were produced by transient transfection of the packaging
cell line Phoenix ampho (a gift from G.P. Nolan, Stanford University, Stan-
ford, CA). HeLa cells were infected with FLAG-Bax and FLAG-Bax(P168A)
viruses in the presence of polybrene, and stable populations were obtained
by selection with G418 (2.5 and 5 mg/ml). To avoid clonal artifacts, se-
lected cell populations, instead of clones, were further used. MEFs defi-
cient in both Bax and Bak (DKO cells, provided by S.J. Korsmeyer, Dana-
Farber Cancer Institute, Boston, MA) were infected with EGFP-Bax and
EGFP-Bax(P168A) viruses and selected by FACS
® sorting. Cytosolic frac-
tions were immunoprecipitated using 5  l anti–N-Bax and 50  l of 50%
(vol/vol) protein A–Sepharose. Immunocomplexes were captured on an
end-over-end wheel at 4 C for 2 h and analyzed by anti-FLAG Western
blotting as described in the previous paragraph.
IVTT
The TNT Quick T7-coupled reticulocyte lysate system (Promega) was used
essentially as described by the manufacturer. IVTT and mitochondrial
membrane association/insertion was performed exactly as described by
Kaufmann et al. (2003).
Cell viability assay
A cotransfection assay was performed in HEK293 cells. Equal numbers of
HEK293 cells were grown in six wells to 70% confluence and cotrans-
fected with 2  g of the desired cDNA and 0.5  g EGFP-C2 (CLONTECH
Laboratories, Inc.; 4:1 molar ratio) using the lipidic transfection reagent
Metafectene (Biontex) as described by the manufacturer. After 24 h, the
cells were trypsinized, centrifuged, and resuspended in 1 ml PBS supple-
mented with 3% FCS and 10  g/ml PI. Quantitative analysis was per-
formed by analyzing 20,000 cells by FACS
® and determining the number
of EGFP-positive/PI-negative cell as a percentage of the total. Similar anal-
yses were performed with EGFP-Bax wild-type and mutant constructs 24 h
after transfection into HEK293 cells. The percentages obtained for cells
transfected with mutant constructs were normalized to that of pcDNA3/
EGFP or EGFP.
To test the apoptosis-rescuing effect of Bax and its mutants, wild-type
MEFs, Bax/Bak DKO MEFs, and Bax/Bak DKO MEFs stably expressing
EGFP-Bax and EGFP-Bax(P168A) were treated with 100  M etoposide for
24 h and subjected to FACS
® analysis in the presence of PI as described in
the previous paragraph. Cell death was quantified by counting the PI-posi-
tive cells.
Online supplemental material
Details about the role of the two positive charges at the COOH terminus of
Bax for mitochondrial targeting, the subcellular localization and cytotoxic-
ity of endogenous and overexpressed Bax and Bak, the cytoplasmic local-
ization of Pro168 mutants of Bax in HEK293 cells, the activity of the TMB-
deleted Bax variants, the stability and integrity of the Bax(P168A) protein,
as well as the methods for gel filtration analysis and the generation of the
various Bax and Bak mutants and the EGFP fusion proteins by PCR or stan-
dard cut and paste techniques can be found as supplemental material. On-
line supplemental material is available at http://www.jcb.org/cgi/content/
full/jcb.200309013/DC1.
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